lncRNA-MEG3通过TLR4/NF-κB信号抑制胰腺癌细胞迁移和侵袭

doi:10.3760/cma.j.cn441417-20241012-08019

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (8): 1321-1326.DOI: 10.3760/cma.j.cn441417-20241012-08019

lncRNA-MEG3通过TLR4/NF-κB信号抑制胰腺癌细胞迁移和侵袭

郑伟¹ 郭栋¹ 吴胜利²

¹陕西省核工业二一五医院普外二科，咸阳 712000；²西安交通大学第一附属医院肝胆外科，西安 710061

收稿日期:2024-10-12 出版日期:2025-04-15 发布日期:2025-04-20
通讯作者: 郭栋，Email：645369495@qq.com
基金资助:
陕西省重点研发计划（2020SF-060）

LncRNA-MEG3 inhibits pancreatic cancer cell migration and invasion through TLR4/NF-κB signaling

Zheng Wei¹, Guo Dong¹, Wu Shengli²

¹Second Department of General Surgery, No.215 Hospital of Shaanxi Nuclear Industry, Xianyang 712000, China; ²The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Received:2024-10-12 Online:2025-04-15 Published:2025-04-20
Contact: Guo Dong, Email: 645369495@qq.com
Supported by:
Key Research Plan of Research and Development in Shaanxi (2020SF-060)

摘要/Abstract

摘要：

目的　通过Toll样受体4（TLR4）及转录因子-κB（NF-κB）信号探究长链非编码RNA（lncRNA）-母系表达基因3（MEG3）对胰腺癌细胞迁移、侵袭的影响。方法　研究时间：2022年1月至2023年1月。将PANC-1（人胰腺癌细胞株）分为空白组（无转染PANC-1细胞），空转组（PANC-1转染pCDHEF1-copGFP pCDH-Scramble），MEG3组（PANC-1转染pCDH-EF1-MEG3–copGFP pCDH-MEG3）。通过实时荧光定量聚合酶链反应（qRT-PCR）检测胰腺癌细胞中lncRNA-MEG3、TLR4/NF-κB表达量，克隆法形成实验检测克隆形成率，流式细胞仪检测PANC-1细胞凋亡率，Transwell小室及划痕实验分别检测胰腺癌细胞侵袭数量、迁移距离。Western blot检测胰腺癌细胞中TLR4、NF-κB、NF-κBp65、髓样分化因子88（MyD88）蛋白表达水平。统计学方法采用t检验、单因素方差分析、SNK-q检验。结果　MEG3组PANC-1细胞克隆形成率、侵袭数量及迁移距离均低于空白组和空转组，PANC-1细胞凋亡率高于空白组和空转组，差异均有统计学意义（F=23.070、99.390、23.980、265.000，均P<0.05）。MEG3组和抑制剂组PANC-1细胞中TLR4、NF-κB、NF-κBp65、MyD88蛋白表达均低于空白组和空转组（均P<0.05）。结论　lncRNA-MEG3能通过抑制TLR4/NF-κB基因表达，调控PANC-1细胞的迁移和侵袭。

关键词:

胰腺癌, 转染, 侵袭, 克隆, 凋亡

Abstract:

Objective　Based on toll-like receptor 4(TLR4) and nuclear factor-kappa B (NF-κB), to explore the effect of long non-coding RNA (lncRNA) and maternal expression gene 3 (MEG3) on migration and invasion of pancreatic cancer cells. Methods　This study was conducted from January 2022 to January 2023. The human pancreatic cancer cell lines were divided into a blank group (no transfected PANC-1 cells), an idle group (transfected pCDHEF1-copGFP pCDH-Scramble with PANC-1), and an MEG3 group (PANC-1 transfection PCDH-EF1-MEG3-COPGFP pCDH-MEG3). The quantitative real-time polymerase chain reaction (QRT-PCR) was used to detect the expressions of lncRNA-MEG3 and TLR4/NF-κB in the pancreatic cancer cells. The clonal formation rate was detected by the clonal assay. The apoptosis rate of the PANC-1 cells was detected by the flow cytometry. The invasion number and migration distance of the pancreatic cancer cells were detected by the Transwell cell and scratch assay. The expression levels of TLR4, NF-κB, NF-κBp65, and myeloid differentiation factor 88 (MyD88) in the pancreatic cancer cells were detected by the Western blot. t test, one-way analysis of variance, and SNK-q test were used for the statistical analysis. Results　The clonal formation rate, invasion number, and migration distance of the PANC-1 cells in the MEG3 group were lower than those in the blank group and the idle group, and the apoptosis rate of the PANC-1 cells was higher, with statistical difference (F=23.070, 99.390, 23.980, and 265.000; all P<0.05). The protein expressions of TLR4, NF-κB, NF-κBp65, and MyD88 of PANC-1 cells in the MEG3 group and the inhibitor group were lower than those in the blank group and the idle group (all P<0.05). Conclusion　LncRNA-MEG3 can regulate the migration and invasion of PANC-1 cells inhibiting the expression of TLR4/NF-κB gene.

Key words:

Pancreatic cancer, Transfection, Invasion, Cloning, Apoptosis

郑伟郭栋吴胜利.

lncRNA-MEG3通过TLR4/NF-κB信号抑制胰腺癌细胞迁移和侵袭 [J]. 国际医药卫生导报, 2025, 31(8): 1321-1326.

Zheng Wei, Guo Dong, Wu Shengli.

LncRNA-MEG3 inhibits pancreatic cancer cell migration and invasion through TLR4/NF-κB signaling [J]. International Medicine and Health Guidance News, 2025, 31(8): 1321-1326.

参考文献

[1] Fan F, Jin L, Yang L. pH-sensitive nanoparticles composed solely of membrane-disruptive macromolecules for treating pancreatic cancer[J]. ACS Appl Mater Interfaces, 2021,13(11):12824-12835.DOI: 10.1021/acsami.0c16576.
[2] Tian X, Traub B, Shi J,et al. c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1[J]. Cancer Gene Ther, 2022,29(1):73-86.DOI: 10.1038/s41417-020- 00290-5.
[3] Kim JH, Lee SC, Oh SY,et al. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study[J]. Cancer Commun (Lond), 2018,38(1):32.DOI: 10.1186/s40880-018-0304-1.
[4] Li Y, Yang N, Zhou X,et al. LncRNA and mRNA interaction study based on transcriptome profiles reveals potential core genes in the pathogenesis of human thoracic aortic dissection[J]. Mol Med Rep, 2018,18(3):3167-3176.DOI: 10.3892/mmr.2018.9308.
[5] Jiang X, Wang L, Xie S,et al. Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically[J]. Stem Cell Res Ther, 2020,11(1):518.DOI: 10.1186/s13287-020-02036-4.
[6] 沈雅婷.非诺贝特上调LncRNA MEG3激活p53抑制胰腺癌细胞的试验研究[D]. 苏州:苏州大学, 2018.
[7] Notas G, Panagiotopoulos A, Vamvoukaki R,et al. ERα36-GPER1 collaboration inhibits TLR4/NFκB-induced pro-inflammatory activity in breast cancer cells[J]. Int J Mol Sci, 2021,22(14):7603.DOI: 10.3390/ijms22147603.
[8] Li Z, Gao H, Liu Y,et al. Genetic variants in the regulation region of TLR4 reduce the gastric cancer susceptibility[J]. Gene, 2021,767:145181.DOI: 10.1016/j.gene.2020. 145181.
[9] 刘心悦,巫燕芬,马子骞,等. 胰腺癌患者临床特征及预后分析[J]. 河北医药,2020,42(11):1615-1619. DOI:10.3969/j.issn.1002-7386.2020.11.003.
[10] Reiss KA, Vonderheide RH. Alternatives to perpetual chemotherapy for metastatic pancreatic cancer[J]. Clin Cancer Res, 2021,27(13):3540-3542.DOI: 10.1158/1078-0432.CCR-21-0612.
[11] Li H, Wang P, Liu J,et al. Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells[J]. J Clin Lab Anal, 2020 ,34(9):e23369.DOI: 10.1002/jcla.23369.
[12] Yan H, Luo B, Wu X,et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer[J]. Int J Biol Sci, 2021,17(10):2606-2621.DOI: 10.7150/ijbs.60292.
[13] Gao L, Shao T, Zheng W,et al. Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling[J]. Clin Transl Oncol, 2021,23(7):1386-1393.DOI: 10.1007/s12094-020-02531-3.
[14] Yang Z, Wang Z, Duan Y. LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein[J]. Oncol Lett, 2020 ,20(3):2183-2190.DOI: 10.3892/ol.2020.11770.
[15] 陈晓雷,杨秀丽,周天竹,等. 雷公藤红素上调lncRNA MEG3表达抑制肝癌细胞增殖及促进细胞凋亡[J]. 现代肿瘤医学,2019,27(5):739-742. DOI:10.3969/j.issn. 1672-4992.2019.05.006.
[16] Zhang Y, Liu J, Lv Y,et al. LncRNA meg3 suppresses hepatocellular carcinoma in vitro and vivo studies[J]. Am J Transl Res, 2019,11(7):4089-4099.
[17] Messaritakis I, Stogiannitsi M, Koulouridi A,et al. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer[J]. PLoS One, 2018,13(6):e0197327. DOI: 10.1371/journal.pone.0197327.
[18] Deveci Ozkan A, Kaleli S, Onen HI,et al. Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells[J]. Immunopharmacol Immunotoxicol, 2020,42(2):93-100.DOI: 10.1080/08923973.2020.1725040.
[19] Zhang L, Shi H, Chen H,et al. Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP/HIF-1α signaling enhances pancreatic cancer stemness[J]. Cell Death Dis, 2019,10(10):724.DOI: 10.1038/s41419-019-1956-8.
[20] 孙运良,马建霞,满晓华,等. p38 MAPK信号通路在TLR4促进胰腺癌血管生成中的作用[J]. 重庆医学,2017,46(2):161-164. DOI:10.3969/j.issn.1671-8348.2017.02.005.
[21] Youn SE, Jiang F, Won HY,et al. PAUF induces migration of human pancreatic cancer cells exclusively via the TLR4/MyD88/NF-κB signaling pathway[J]. Int J Mol Sci, 2022,23(19):11414. DOI: 10.3390/ijms231911414.
[22] Yoon JH, Shin JW, Pham TH,et al. Methyl lucidone induces apoptosis and G2/M phase arrest via the PI3K/Akt/NF-κB pathway in ovarian cancer cells[J]. Pharm Biol, 2020,58(1):51-59.DOI: 10.1080/13880209.2019. 1701044.
[23] 孙联康,都大伟,钱伟崐,等. 趋化因子CXCL11激活NF-κB信号通路促进胰腺癌的侵袭转移及上皮间质转换[J]. 西安交通大学学报(医学版),2019,40(4):501-505. DOI:10.7652/jdyxb201904002.
[24] Suhail M, Tarique M, Muhammad N,et al. A critical transcription factor NF-κB as a cancer therapeutic target and its inhibitors as cancer treatment options[J]. Curr Med Chem, 2021,28(21):4117-4132.DOI: 10.2174/0929867327666201111142307.
[25] 陈鹏,崔锐,梁鸿飞,等. miR-195靶向TLR4并阻断NF-κB通路抑制肝癌细胞HepG2增殖和转移[J]. 中国肿瘤生物治疗杂志,2019,26(5):550-556. DOI:10.3872/j.issn. 1007-385x.2019.05.011.
[26] Tao XW, Zeng LK, Wang HZ,et al. LncRNA MEG3 ameliorates respiratory syncytial virus infection by suppressing TLR4 signaling[J]. Mol Med Rep, 2018 ,17(3):4138-4144. DOI: 10.3892/mmr.2017.8303.

lncRNA-MEG3通过TLR4/NF-κB信号抑制胰腺癌细胞迁移和侵袭

LncRNA-MEG3 inhibits pancreatic cancer cell migration and invasion through TLR4/NF-κB signaling

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	曹马狄王科杨爱民. 赤芍总苷抑制甲状腺癌细胞恶性行为的机制研究 [J]. 国际医药卫生导报, 2025, 31(8): 1275-1282.
[2]	莫家婵范万峰姜兴岳. 基于磁共振成像的影像组学在垂体腺瘤中的应用现状及进展 [J]. 国际医药卫生导报, 2025, 31(5): 757-760.
[3]	张国腾王毅周沛邱世诚周剑鹏. 富血小板血浆对白细胞介素-1β诱导大鼠髓核细胞凋亡的影响 [J]. 国际医药卫生导报, 2025, 31(4): 591-596.
[4]	王玮丁伯勇. 高压氧对子宫内膜癌细胞增殖、凋亡及HIF-1α/VEGF信号通路的影响 [J]. 国际医药卫生导报, 2025, 31(4): 622-626.
[5]	董璐莹王越淇黄晓程王佳. 沉默lncRNA Gm9866表达对高糖诱导的胰岛β细胞损伤的保护作用[J]. 国际医药卫生导报, 2025, 31(2): 177-182.
[6]	李香玉郑慧娟樊艳婷. 儿童流感嗜血杆菌感染特点及疾病进展的影响因素 [J]. 国际医药卫生导报, 2025, 31(2): 265-269.
[7]	徐腾飞刘金立朱永村. 伴单克隆B淋巴细胞和单克隆浆细胞增殖的AITL 1例 [J]. 国际医药卫生导报, 2024, 30(7): 1195-1198.
[8]	谭艳华江龙邹素娟侯杰王云旷昕. 右美托咪定经STAT3/FoxO3a信号转导通路对减轻H9C2心肌细胞缺氧/复氧损伤的作用 [J]. 国际医药卫生导报, 2024, 30(20): 3345-3350.
[9]	谌登珍马强. circMBOAT2靶向miR-526b-3p对肺癌A549细胞增殖和凋亡的影响 [J]. 国际医药卫生导报, 2024, 30(20): 3363-3368.
[10]	赵辽辽常露元曹丽. 血游离轻链与M蛋白检测在膜性肾病合并MGUS患者中的临床意义 [J]. 国际医药卫生导报, 2024, 30(17): 2894-2899.
[11]	黄毅王琮翰. YAP2基因对大鼠H9c2心肌细胞凋亡及TNF-α和IL-6水平的影响 [J]. 国际医药卫生导报, 2024, 30(14): 2297-2302.
[12]	郑晓意林丹霞. Claudin18.2在实体瘤中的研究进展 [J]. 国际医药卫生导报, 2024, 30(12): 1941-1945.
[13]	姚文杰宋凯雨姜冠桐陈茜周瑾. 桥本甲状腺炎的研究进展 [J]. 国际医药卫生导报, 2023, 29(6): 741-744.
[14]	陈思奇彭荣东徐嘉琪冯俊霞周晓莹张云芳苏妍妍. Drp1介导线粒体能量代谢拮抗大鼠缺血再灌注肾损伤 [J]. 国际医药卫生导报, 2023, 29(5): 663-669.
[15]	王怡民李清华. 小分子热休克蛋白与肿瘤凋亡关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(3): 297-301.